Phase IIa study demonstrates that novel maturation inhibitor exhibits dose-response antiviral activity, in vivo concentrations above clinical efficacy targets, and good tolerability.
Racial and ethnic disparities are evident among PWH testing positive for COVID-19 in the United States.
Both PrEP regimens were highly effective in preventing HIV infection in this open-label study.
Longitudinal analysis of HIV infections, viral load, cabotegravir concentrations, and emergent resistance in HPTN 083 demonstrated the importance of prompt diagnosis and initiation of ART to avoid resistance in cases of breakthrough infection with long-acting cabotegravir as PrEP.
Among South African women COVID-19 was associated with an increased maternal mortality rate in high-risk pregnancy but pregnancy and neonatal outcomes were generally similar with vs without HIV infection.
Superior virologic efficacy observed with DTG-based regimen vs EFV-based regimen throughout pregnancy and through the breastfeeding period: final results of the DolPHIN-2 study.
In this randomized noninferiority trial, the overall safety and efficacy of DTG plus FTC/TAF or FTC/TDF was generally similar to EFV/FTC/TDF when initiated during pregnancy, but in post hoc analyses, infant mortality, virologic failure at ≥ 24 weeks, and maternal weight loss were all higher with EFV/FTC/TDF vs DTG-based regimens.
Long-acting cabotegravir plus rilpivirine injections every 2 months are noninferior to monthly injections at Week 96 in virologically suppressed patients with no prior virologic failure.
Study finds that use of genotypic resistance testing to guide management of patients experiencing first-line ART failure does not improve viral suppression rates, highlighting need for alternative strategies to improve management of ART failure.
Higher levels of immune activation biomarkers more strongly predict vascular events in virologically suppressed women with HIV compared with virologically suppressed men with HIV.